Expression of target molecules in XXXX : challenge for a new treatment paradigm.

@entity1 @entity5 @entity2 @entity3 @entity105
@entity2 is the leading cause of @entity5 in @entity1 and @entity1 in the United States, accounting for 28% of all @entity5 fatalities. More than two thirds of @entity1 present with metastatic disease at the time of presentation. Despite improvements in chemotherapy and combined treatment modalities, the survival rate remains below 15%. However, recent advances in our understanding of the biology of @entity2 and @entity105 have led to the development of novel therapies directed at @entity5 -specific targets. These targets are crucial components in important pathways for cell growth, proliferation, and apoptosis. Strategies that interfere with these pathways include monoclonal antibodies directed at growth factors or their receptors, immunotoxins, ligand toxins, antisense molecules, ribozymes, and small-molecule inhibitors. Novel cell surface antigens are being used in vaccines developed to stimulate T-cell-specific immunity. The @entity5 cells also have specific survival requirements in their local environment that are necessary for invasion, angiogenesis, and @entity3 . Many new therapeutic strategies are designed to interfere with these requirements. This article reviews many of these recent developments and new therapeutic possibilities; ideally, in the near future, these developments will be implemented in the treatment of @entity2 @entity1 and in early detection and chemoprevention strategies.
